WO2013127970A1 - Pharmazeutische zubereitung enthaltend ein antiviral wirksames dihydrochinazolinderivat - Google Patents

Pharmazeutische zubereitung enthaltend ein antiviral wirksames dihydrochinazolinderivat Download PDF

Info

Publication number
WO2013127970A1
WO2013127970A1 PCT/EP2013/054114 EP2013054114W WO2013127970A1 WO 2013127970 A1 WO2013127970 A1 WO 2013127970A1 EP 2013054114 W EP2013054114 W EP 2013054114W WO 2013127970 A1 WO2013127970 A1 WO 2013127970A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical preparation
solution
phenyl
salt
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2013/054114
Other languages
German (de)
English (en)
French (fr)
Inventor
Kerstin Paulus
Wilfried Schwab
Dominique Grunder
Peter Van Hoogevest
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aicuris GmbH and Co KG
Original Assignee
Aicuris GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47757622&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2013127970(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to UAA201410519A priority Critical patent/UA111415C2/uk
Priority to ES13707000T priority patent/ES2741698T3/es
Priority to AU2013224947A priority patent/AU2013224947B2/en
Priority to NZ628444A priority patent/NZ628444A/en
Priority to CA2865203A priority patent/CA2865203C/en
Priority to IN1892MUN2014 priority patent/IN2014MN01892A/en
Priority to BR112014020946-4A priority patent/BR112014020946B1/pt
Priority to EP13707000.9A priority patent/EP2819648B1/de
Priority to LTEP13707000.9T priority patent/LT2819648T/lt
Priority to PH1/2014/501937A priority patent/PH12014501937B1/en
Priority to MX2014010364A priority patent/MX369666B/es
Priority to DK13707000.9T priority patent/DK2819648T3/da
Priority to EA201400963A priority patent/EA026584B1/ru
Priority to RSP20191076 priority patent/RS59157B1/sr
Priority to PL13707000T priority patent/PL2819648T3/pl
Priority to HRP20191369 priority patent/HRP20191369T1/hr
Priority to KR1020147023803A priority patent/KR102149561B1/ko
Application filed by Aicuris GmbH and Co KG filed Critical Aicuris GmbH and Co KG
Priority to JP2014559233A priority patent/JP6387486B2/ja
Priority to EP24150976.9A priority patent/EP4328218A3/de
Priority to HK15106080.1A priority patent/HK1205462B/xx
Priority to MEP-2019-219A priority patent/ME03448B/me
Priority to EP19176985.0A priority patent/EP3556350B1/de
Priority to SI201331541T priority patent/SI2819648T1/sl
Priority to SM20190458T priority patent/SMT201900458T1/it
Priority to CN201380011670.7A priority patent/CN104144678A/zh
Priority to US14/381,290 priority patent/US10603384B2/en
Priority to SG11201405294XA priority patent/SG11201405294XA/en
Priority to MYPI2014002461A priority patent/MY172310A/en
Publication of WO2013127970A1 publication Critical patent/WO2013127970A1/de
Priority to TNP2014000345A priority patent/TN2014000345A1/fr
Priority to ZA2014/05949A priority patent/ZA201405949B/en
Priority to IL234363A priority patent/IL234363B/en
Anticipated expiration legal-status Critical
Priority to MA37360A priority patent/MA35941B1/fr
Priority to CY20191100885T priority patent/CY1121910T1/el
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms

Definitions

  • the invention furthermore relates to pharmaceutical preparations which are prepared by lyophilizing the abovementioned pharmaceutical preparation.
  • a cyclodextrin according to the invention is understood to mean any modified or unmodified cyclodextrin. Due to the size of the cavity in the ring, ⁇ -cyclodextrins and in particular modified ⁇ -cyclodextrins such as, for example, hydroxyalkyl- ⁇ -cyclodextrins, for example hydroxymethyl- ⁇ -cyclodextrin, hydroxyethyl- ⁇ -cyclodextrin or hydroxypropyl- ⁇ -cyclodextrin, alkylhydroxyalkyl- ⁇ -cyclodextrins, for example methylhydroxypropyl- ⁇ -cyclodextrins or ethylhydroxypropylcyclodextrins or sulphoalkylcyclodextrins.
  • hydroxyalkyl- ⁇ -cyclodextrins for example hydroxymethyl- ⁇ -cyclodextrin, hydroxyethyl- ⁇ -cyclodextrin or hydroxy
  • the at least one adjuvant is used in an amount of from 1 to 5 equivalents, preferably from 2 to 5 equivalents and more preferably from 2.5 to 4.5 equivalents based on the content of ⁇ 8-fluoro -2- [4- (3-methoxyphenyl) piperazin-1-yl] -3 - [2-methoxy-5 - (trifluoromethyl) phenyl] -3,4-dihydroquinazolin-4-yl ⁇ acetic acid is present in the pharmaceutical preparation ,
  • the pharmaceutical preparations according to the invention are generally prepared by first preparing an aqueous solution of the excipient and then ⁇ 8-fluoro-2- [4- (3-methoxyphenyl) piperazin-1-yl] -3 - [2-methoxy -5- (trifluoromethyl) phenyl] -3,4-dihydroquinazolin-4-yl ⁇ acetic acid is added to this solution, optionally followed by addition of other additives such as the at least one sugar and / or the at least one buffer.
  • the invention thus also provides a process for preparing a pharmaceutical preparation according to the invention with the following steps: A) dissolving the at least one excipient in the water,
  • the compound of the formula (V) can be prepared by reacting a compound of the form
  • bases examples include amine bases such as 1,8-diazabicyclo [5.4.0] undec-7-ene (DBU), 1- (3-methoxyphenyl) piperazine or triethylamine, or other bases such as potassium tert-butoxide.
  • DBU 1,8-diazabicyclo [5.4.0] undec-7-ene
  • 1- (3-methoxyphenyl) piperazine or triethylamine or other bases such as potassium tert-butoxide.
  • Inert solvents are, for example, hydrocarbons such as benzene, xylene, toluene or chlorobenzene.
  • DBU is in chlorobenzene.
  • bases in the second stage are DBU, triethylamine or diisopropylethylamine.
  • Method 1 Instrument: HP 1050 with variable wavelength detection; Column: Phenomenex-Prodigy ODS (3) 100A, 150 mm x 3 mm, 3 ⁇ ; Eluent A: (1.0 g KH 2 P0 4 + 1.0 mL H 3 PO 4 ) / 1 water, eluent B: acetonitrile; Gradient: 0 min 10% B, 25 min 80% B, 35 min 80% B; Flow: 0.5 ml / min; Temp .: 45 ° C; UV detection: 210 nm.
  • Method 3 Instrument: HP 1050 with variable wavelength detection; Column: Chiral AD-H, 250 mm x 4.6 mm, 5 ⁇ ; Eluent A: n-heptane + 0.2% diethylamine, eluent B: isopropanol + 0.2% diethylamine; Gradient: 0 min 25% B, 15 min 25% B; Flow: 1 ml / min; Temperature: 30 ° C; UV detection: 250 nm.
  • the reaction mixture is cooled to room temperature, hydrolyzed by adding in water, diluted with chlorobenzene (80 L) and neutralized with aqueous ammonia solution (25%). The phases are separated and the organic phase washed with water and the solvent distilled off. The remaining residue is dissolved in dioxane (170 l). 3-Methoxyphenylpiperazine (66 Kg), DBU (52 Kg) and another 90 L of dioxane are added and the reaction mixture is heated at reflux for 4 hours. The reaction mixture is cooled to room temperature, treated with ethyl acetate (1300 1), once with water, 3 times with 0.2 N HCl, and once with aqueous NaCl solution and the solvent is distilled off.
  • hydroxypropyl- ⁇ -cyclodextrin HP5 (Kieptose HPB, Roquette) are mixed with 68.365 g of water for injection and 6.6 g of a 1 M sodium hydroxide solution are added to the mixture.
  • a 1 M sodium hydroxide solution After adding 5.005 g of the compound of Example 6A, the mixture is warmed to 50 ° C and stirred for 24 h until a clear solution is formed.
  • the solution is sterile filtered (pore diameter 0.22 ⁇ ) and filled under aseptic conditions in sterile 20 ml glass containers. The filled glass containers are sealed with infusion stoppers and crimp caps.
  • Example 2 by varying the amount of the first stock solution also pharmaceutical preparations with other concentrations of ⁇ 8-fluoro-2- [4- (3-methoxyphenyl) piperazine-1-yl] -3- [2-methoxy-5 - (trifluoromethyl) phenyl] -3,4-dihydroquinazolin-4-yl ⁇ acetic acid.
  • the described solution may be diluted with an isotonic solution, for example an isotonic infusion solution.
  • Example 8 The solution of Example 8 is used without further dilution in the test.
  • the compound of Example 6A is used as 50 millimolar (mM) solutions in dimethylsulfoxide (DMSO).
  • DMSO dimethylsulfoxide
  • Ganciclovir®, Foscarnet® or Cidofovir® can be used as reference compounds.
  • 1.5 ⁇ 10 4 human foreskin fibroblasts (NHDF cells) / well are seeded in 200 ⁇ l cell culture medium into the wells B2-G1 1 of 96-well plates (black with transparent bottom). The marginal wells of each 96-well plate are filled only with 200 ⁇ 1 medium to avoid edge effects.
  • the virus used is a recombinant HCMV which has integrated an expression cassette for the green fluorescence protein (GFP) into the virus genome (HCMV AD 169 RV-HG (Borst EM, K. Wagner, A. Binz, B. Sodeik, and M. Messerle, 2008, J.
  • GFP green fluorescence protein
  • the plates are incubated for 7 days at 37 ° C / 5% C0 2 . Subsequently, all wells of a plate are washed 3 times with PBS (Phosphate Buffered Saline) and filled with 50 ⁇ M PBS. Thereafter, the GFP intensity of each well of a 96-well plate is determined by means of a fluorescence reader (FluoBox, Bayer Technology Services GmbH, filter settings: GFP, Ex 480nm s Em 520nm). From the measured values thus obtained, the EC50 of an anti-HCMV substance can be determined:

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PCT/EP2013/054114 2012-02-29 2013-02-28 Pharmazeutische zubereitung enthaltend ein antiviral wirksames dihydrochinazolinderivat Ceased WO2013127970A1 (de)

Priority Applications (33)

Application Number Priority Date Filing Date Title
MYPI2014002461A MY172310A (en) 2012-02-29 2013-02-28 Pharmaceutical preparation containing an antivirally active dihydroquinazoline derivative
JP2014559233A JP6387486B2 (ja) 2012-02-29 2013-02-28 抗ウイルス活性ジヒドロキナゾリン誘導体を含有する医薬組成物
AU2013224947A AU2013224947B2 (en) 2012-02-29 2013-02-28 Pharmaceutical preparation containing an antivirally active dihydroquinazoline derivative
NZ628444A NZ628444A (en) 2012-02-29 2013-02-28 Pharmaceutical preparation containing an antivirally active dihydroquinazoline derivative
CA2865203A CA2865203C (en) 2012-02-29 2013-02-28 Pharmaceutical composition containing an antivirally active dihydroquinazoline derivative
HK15106080.1A HK1205462B (en) 2012-02-29 2013-02-28 Pharmaceutical preparation comprising an antiviral dihydroquinazoline derivative
BR112014020946-4A BR112014020946B1 (pt) 2012-02-29 2013-02-28 Preparação farmacêutica para administração intravenosa, preparação farmacêutica sólida, método para produção de uma preparação farmacêutica e uso de uma preparação farmacêutica
EP13707000.9A EP2819648B1 (de) 2012-02-29 2013-02-28 Pharmazeutische zubereitung enthaltend ein antiviral wirksames dihydrochinazolinderivat
LTEP13707000.9T LT2819648T (lt) 2012-02-29 2013-02-28 Farmacinis preparatas, turintis priešvirusinį veiksmingą dihidrochinazolino darinį
PH1/2014/501937A PH12014501937B1 (en) 2012-02-29 2013-02-28 Pharmaceutical composition containing an antivirally active dihydroquinazoline derivative
MX2014010364A MX369666B (es) 2012-02-29 2013-02-28 Composicion farmaceutica que contiene un derivado de dihidroquinazolina antiviralmente activo.
DK13707000.9T DK2819648T3 (da) 2012-02-29 2013-02-28 Farmaceutisk præparat omfattende et antiviralt virksomt dihydroquinazolinderivat
EA201400963A EA026584B1 (ru) 2012-02-29 2013-02-28 Фармацевтический препарат, содержащий производное дигидрохиназолина с противовирусной активностью
RSP20191076 RS59157B1 (sr) 2012-02-29 2013-02-28 Farmaceutski preparat koji obuhvata antivirusno efikasan derivat dihidrohinazolina
PL13707000T PL2819648T3 (pl) 2012-02-29 2013-02-28 Preparat farmaceutyczny zawierający pochodną dihydrochinazoliny o działaniu przeciwwirusowym
HRP20191369 HRP20191369T1 (hr) 2012-02-29 2013-02-28 Farmaceutski pripravak koji sadrži antivirusni derivat dihidrokvinazolina
KR1020147023803A KR102149561B1 (ko) 2012-02-29 2013-02-28 항바이러스 활성 디히드로퀴나졸린 유도체를 함유하는 제약 제제
UAA201410519A UA111415C2 (uk) 2012-02-29 2013-02-28 Фармацевтичний препарат, що містить похідну дигідрохіназоліну з противірусною активністю
EP24150976.9A EP4328218A3 (de) 2012-02-29 2013-02-28 Pharmazeutische zubereitung enthaltend ein antiviral wirksames dihydrochinazolinderivat
ES13707000T ES2741698T3 (es) 2012-02-29 2013-02-28 Preparado farmacéutico que contiene un derivado antiviral de dihidroquinazolina
IN1892MUN2014 IN2014MN01892A (OSRAM) 2012-02-29 2013-02-28
MEP-2019-219A ME03448B (me) 2012-02-29 2013-02-28 Farmaceutski preparat којi obuhvata antivirusno efikasan derivat dihidrohinazolina
EP19176985.0A EP3556350B1 (de) 2012-02-29 2013-02-28 Pharmazeutische zubereitung enthaltend ein antiviral wirksames dihydrochinazolinderivat mit s-konfiguration in position 4
SI201331541T SI2819648T1 (sl) 2012-02-29 2013-02-28 Farmacevtski pripravek, ki vsebuje protivirusno učinkovit dihidrokinazolinski derivat
SM20190458T SMT201900458T1 (it) 2012-02-29 2013-02-28 Preparazione farmaceutica contenente un derivato di diidrocinazolo efficace antivirale
CN201380011670.7A CN104144678A (zh) 2012-02-29 2013-02-28 含有抗病毒活性二氢喹唑啉衍生物的药物制剂
US14/381,290 US10603384B2 (en) 2012-02-29 2013-02-28 Pharmaceutical composition containing an antivirally active dihydroquinazoline derivative
SG11201405294XA SG11201405294XA (en) 2012-02-29 2013-02-28 Pharmaceutical preparation containing an antivirally active dihydroquinazoline derivative
TNP2014000345A TN2014000345A1 (en) 2012-02-29 2014-08-08 Pharmaceutical preparation containing an antivirally active dihydroquinazoline derivative
ZA2014/05949A ZA201405949B (en) 2012-02-29 2014-08-13 Pharmaceutical preparation containing and antivirally active dihydroquinazoline derivative
IL234363A IL234363B (en) 2012-02-29 2014-08-28 Pharmaceutical preparation containing an antivirally active dihydroquinazoline derivative
MA37360A MA35941B1 (fr) 2012-02-29 2014-09-17 Préparation pharmaceutique contenant un dérivé de dihydrochinazoline à action antivirale
CY20191100885T CY1121910T1 (el) 2012-02-29 2019-08-20 Φαρμακευτικο παρασκευασμα που περιεχει παραγωγο διυδροκιναζολινης με αντιϊικη δραση

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102012101680.1 2012-02-29
DE102012101680A DE102012101680A1 (de) 2012-02-29 2012-02-29 Pharmazeutische Zubereitung enthaltend ein antiviral wirksames Dihydrochinazolinderivat

Publications (1)

Publication Number Publication Date
WO2013127970A1 true WO2013127970A1 (de) 2013-09-06

Family

ID=47757622

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2013/054114 Ceased WO2013127970A1 (de) 2012-02-29 2013-02-28 Pharmazeutische zubereitung enthaltend ein antiviral wirksames dihydrochinazolinderivat

Country Status (37)

Country Link
US (1) US10603384B2 (OSRAM)
EP (3) EP2819648B1 (OSRAM)
JP (1) JP6387486B2 (OSRAM)
KR (1) KR102149561B1 (OSRAM)
CN (2) CN110433166A (OSRAM)
AU (1) AU2013224947B2 (OSRAM)
BR (1) BR112014020946B1 (OSRAM)
CA (1) CA2865203C (OSRAM)
CL (1) CL2014002306A1 (OSRAM)
CO (1) CO7061076A2 (OSRAM)
CY (1) CY1121910T1 (OSRAM)
DE (1) DE102012101680A1 (OSRAM)
DK (2) DK3556350T3 (OSRAM)
EA (1) EA026584B1 (OSRAM)
ES (2) ES2972133T3 (OSRAM)
FI (1) FI3556350T3 (OSRAM)
HR (2) HRP20240197T1 (OSRAM)
HU (2) HUE065553T2 (OSRAM)
IL (1) IL234363B (OSRAM)
IN (1) IN2014MN01892A (OSRAM)
LT (2) LT2819648T (OSRAM)
MA (1) MA35941B1 (OSRAM)
ME (1) ME03448B (OSRAM)
MX (1) MX369666B (OSRAM)
MY (1) MY172310A (OSRAM)
NZ (1) NZ628444A (OSRAM)
PH (1) PH12014501937B1 (OSRAM)
PL (2) PL2819648T3 (OSRAM)
PT (2) PT3556350T (OSRAM)
RS (2) RS59157B1 (OSRAM)
SG (1) SG11201405294XA (OSRAM)
SI (2) SI2819648T1 (OSRAM)
SM (2) SMT202400068T1 (OSRAM)
TN (1) TN2014000345A1 (OSRAM)
UA (1) UA111415C2 (OSRAM)
WO (1) WO2013127970A1 (OSRAM)
ZA (1) ZA201405949B (OSRAM)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016522238A (ja) * 2013-06-19 2016-07-28 アイキュリス アンチ−インフェクティブ キュアズ ゲゼルシャフト ミット ベシュレンクテル ハフツング 非晶質レテルモビル及び経口投与のためのその固形医薬製剤
WO2021170875A1 (en) 2020-02-27 2021-09-02 Aic246 Gmbh & Co. Kg Pharmaceutical compositions comprising 2-[(4s)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4h-quinazolin-4-yl]acetate and sodium ions
WO2021170878A1 (en) 2020-02-27 2021-09-02 Aic246 Gmbh & Co. Kg Sodium 2-[(4s)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4h-quinazolin-4-yl]acetate and pharmaceutical compositions thereof
CN114539085A (zh) * 2020-11-26 2022-05-27 山东诚创蓝海医药科技有限公司 一种脲基衍生物的制备
WO2023118300A1 (en) 2021-12-21 2023-06-29 Aic246 Ag & Co. Kg Pharmaceutical compositions comprising 2-[(4s)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4h-quinazolin-4-yl]acetate and potassium ions

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10319612A1 (de) 2003-05-02 2004-11-18 Bayer Healthcare Ag Substituierte Dihydrochinazoline
AU2017274722A1 (en) 2016-06-03 2019-01-17 Atreya Innovations Private Limited A device for the detection and reliable capturing of the pulse characteristics
ES3015371T3 (en) 2017-03-06 2025-05-05 Venatorx Pharmaceuticals Inc Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof
CN115403528B (zh) * 2021-05-27 2025-01-07 南京正大天晴制药有限公司 无定形3,4-二氢喹唑啉衍生物的制备方法
CN113880776B (zh) * 2021-11-16 2023-06-16 山东诚创蓝海医药科技有限公司 一种莱特莫韦中间体的制备方法
CN118574603A (zh) * 2022-02-23 2024-08-30 株式会社Lg化学 包含异𫫇唑啉衍生物的注射制剂及其制备方法
CN115322157B (zh) * 2022-06-02 2023-12-05 浙江车头制药股份有限公司 来特莫韦中间体化合物及其制备方法和应用
WO2024037485A1 (zh) * 2022-08-15 2024-02-22 上海迪赛诺化学制药有限公司 一种来特莫韦无定形的制备方法
CN115677539B (zh) * 2022-11-01 2023-10-24 南京工业大学 一种温和条件下钴催化脲基导向芳烃的高选择性单烯基化的方法
CN119015222A (zh) * 2024-08-28 2024-11-26 石家庄四药有限公司 一种来特莫韦注射液及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001091751A1 (en) * 2000-05-30 2001-12-06 Novo Nordisk A/S New pharmaceutical composition and the process for its preparation
WO2004096778A1 (de) 2003-05-02 2004-11-11 Bayer Healthcare Ag Substituierte dihydrochinazoline mit antiviralen eigenschaften
WO2006133822A1 (de) 2005-06-15 2006-12-21 Bayer Healthcare Ag Verfahren zur herstellung von dihydrochinazolinen

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1242699A (en) * 1985-02-01 1988-10-04 Bristol-Myers Company Cefbuperazone and derivatives thereof
CA1284994C (en) * 1985-08-05 1991-06-18 Murray Arthur Kaplan Cephalosporin salts and injectable compositions
JP3552240B2 (ja) * 1993-02-23 2004-08-11 第一製薬株式会社 高濃度ｔｃｆ製剤
JPH11209277A (ja) * 1998-01-19 1999-08-03 Yoshitomi Pharmaceut Ind Ltd 医薬組成物
IT1304190B1 (it) * 1998-12-18 2001-03-08 Euphar Group Srl Clatrati di deidroepiandrosterone e relative composizionifarmaceutiche
AU761453B2 (en) * 1999-03-17 2003-06-05 Astrazeneca Ab Amide derivatives
KR20060127413A (ko) * 2003-11-25 2006-12-12 카이론 코포레이션 항암제로서의 퀴나졸리논 화합물
WO2006086464A2 (en) * 2005-02-10 2006-08-17 Bristol-Myers Squibb Company Dihydroquinazolinones as 5ht modulators
US8743287B2 (en) * 2009-07-24 2014-06-03 Broadcom Corporation Method and system for mitigating motion trail artifacts and improving low contrast contours in temporal filtering based noise reduction

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001091751A1 (en) * 2000-05-30 2001-12-06 Novo Nordisk A/S New pharmaceutical composition and the process for its preparation
WO2004096778A1 (de) 2003-05-02 2004-11-11 Bayer Healthcare Ag Substituierte dihydrochinazoline mit antiviralen eigenschaften
PT1622880E (pt) * 2003-05-02 2007-06-04 Aicuris Gmbh & Co Kg ''di-hidroquinazolinas substituídas com propriedades antivirais''
WO2006133822A1 (de) 2005-06-15 2006-12-21 Bayer Healthcare Ag Verfahren zur herstellung von dihydrochinazolinen

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
E. M. BORST; K. WAGNER; A. BINZ; B. SODEIK; M. MESSERLE, J VIROL., vol. 82, 2008, pages 2065 - 2078
J. CINATL ET AL., FEMS MICROBIOLOGY REVIEWS, vol. 28, 2004, pages 59 - 77

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016522238A (ja) * 2013-06-19 2016-07-28 アイキュリス アンチ−インフェクティブ キュアズ ゲゼルシャフト ミット ベシュレンクテル ハフツング 非晶質レテルモビル及び経口投与のためのその固形医薬製剤
WO2021170875A1 (en) 2020-02-27 2021-09-02 Aic246 Gmbh & Co. Kg Pharmaceutical compositions comprising 2-[(4s)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4h-quinazolin-4-yl]acetate and sodium ions
WO2021170878A1 (en) 2020-02-27 2021-09-02 Aic246 Gmbh & Co. Kg Sodium 2-[(4s)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4h-quinazolin-4-yl]acetate and pharmaceutical compositions thereof
CN114539085A (zh) * 2020-11-26 2022-05-27 山东诚创蓝海医药科技有限公司 一种脲基衍生物的制备
CN114539085B (zh) * 2020-11-26 2023-10-20 山东诚创蓝海医药科技有限公司 一种脲基衍生物的制备
WO2023118300A1 (en) 2021-12-21 2023-06-29 Aic246 Ag & Co. Kg Pharmaceutical compositions comprising 2-[(4s)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4h-quinazolin-4-yl]acetate and potassium ions

Also Published As

Publication number Publication date
EP2819648A1 (de) 2015-01-07
EP2819648B1 (de) 2019-05-29
MX369666B (es) 2019-11-14
SMT201900458T1 (it) 2019-11-13
AU2013224947A1 (en) 2014-09-18
EP3556350A1 (de) 2019-10-23
CA2865203A1 (en) 2013-09-06
EP4328218A2 (de) 2024-02-28
IN2014MN01892A (OSRAM) 2015-07-10
US10603384B2 (en) 2020-03-31
HUE045949T2 (hu) 2020-01-28
DK2819648T3 (da) 2019-08-26
MX2014010364A (es) 2014-12-05
CA2865203C (en) 2019-11-05
AU2013224947B2 (en) 2017-06-29
HRP20191369T1 (hr) 2019-11-01
BR112014020946A2 (OSRAM) 2017-06-20
DE102012101680A1 (de) 2013-08-29
ES2972133T3 (es) 2024-06-11
IL234363B (en) 2020-04-30
RS59157B1 (sr) 2019-10-31
UA111415C2 (uk) 2016-04-25
HUE065553T2 (hu) 2024-06-28
SI2819648T1 (sl) 2019-10-30
NZ628444A (en) 2016-07-29
PH12014501937B1 (en) 2022-07-15
CN110433166A (zh) 2019-11-12
KR102149561B1 (ko) 2020-08-31
HK1205462A1 (en) 2015-12-18
BR112014020946B1 (pt) 2022-04-05
ZA201405949B (en) 2021-07-28
LT2819648T (lt) 2019-09-10
CO7061076A2 (es) 2014-09-19
PL2819648T3 (pl) 2019-10-31
JP6387486B2 (ja) 2018-09-12
MY172310A (en) 2019-11-21
PH12014501937A1 (en) 2014-11-24
SG11201405294XA (en) 2014-11-27
EP3556350B1 (de) 2024-01-10
PL3556350T3 (pl) 2024-05-06
US20150133461A1 (en) 2015-05-14
CN104144678A (zh) 2014-11-12
JP2015508801A (ja) 2015-03-23
TN2014000345A1 (en) 2015-12-21
KR20140130683A (ko) 2014-11-11
CL2014002306A1 (es) 2014-11-28
DK3556350T3 (da) 2024-02-12
SI3556350T1 (sl) 2024-03-29
RS65137B1 (sr) 2024-02-29
SMT202400068T1 (it) 2024-03-13
CY1121910T1 (el) 2020-10-14
EA201400963A1 (ru) 2015-02-27
ES2741698T3 (es) 2020-02-12
ME03448B (me) 2020-01-20
MA35941B1 (fr) 2014-12-01
HRP20240197T1 (hr) 2024-04-26
EP4328218A3 (de) 2024-04-10
FI3556350T3 (fi) 2024-02-14
PT3556350T (pt) 2024-02-15
PT2819648T (pt) 2019-09-05
EA026584B1 (ru) 2017-04-28
LT3556350T (lt) 2024-02-26

Similar Documents

Publication Publication Date Title
EP2819648B1 (de) Pharmazeutische zubereitung enthaltend ein antiviral wirksames dihydrochinazolinderivat
EP2820001B1 (de) Natrium- und calciumsalze eines dihydrochinazolinderivates und ihre verwendung als antivirale mittel
EP2820000B1 (de) Besylat- und tosylatsalze eines dihydrochinazolinderivates und ihre verwendung als antivirale mittel
DE2120495A1 (de) Neue Trialkoxychinazolin-Verbindungen und Verfahren zu ihrer Herstellung
WO2004096778A1 (de) Substituierte dihydrochinazoline mit antiviralen eigenschaften
DE10163992A1 (de) 4-Aryl-chinazoline
US9073899B2 (en) Solid forms of dabigatran etexilate mesylate and processes for their preparation
DE2316920B2 (de) Benzo eckige klammer auf d eckige klammer zu eckige klammer auf 1,3 eckige klammer zu dioxolderivate, deren herstellung und diese enthaltende arzneimittel
DE69112192T2 (de) Antiherpes-Castanosperminester.
DE2231067A1 (de) Phenoxathiinderivate mit antiviraler wirkung, verfahren zu ihrer herstellung sowie pharmazeutische praeparate mit einem gehalt an phenoxathiinderivaten
DE69420514T2 (de) Cyclopropan-Derivate und diese enthaltende antivirale Mittel
CH646958A5 (de) 6-aryl- und 6-heteroaryl-pyrimidin-derivate.
HK40014816B (en) Pharmaceutical preparation comprising an antiviral dihydroquinazoline derivative with s configuration in position 4
DE69500156T2 (de) Imidazopyridin-Derivate und Verfahren zu ihrer Herstellung
DD146459A5 (de) Verfahren zur herstellung von n-(1-methyl-2-pyrrolidinylmethyl)-2,3-dimethoxy-5-methylsulphamoylbenzamid und seiner derivate
RU2475481C1 (ru) 2-нитрогетерилтиоцианаты для лечения грибковых инфекций, фармацевтическая композиция и их применение
HK40014816A (en) Pharmaceutical preparation comprising an antiviral dihydroquinazoline derivative with s configuration in position 4
HK1205462B (en) Pharmaceutical preparation comprising an antiviral dihydroquinazoline derivative
DD245198A1 (de) Verfahren zur herstellung von 2-aminoalkylamino-3-cyan-5-(pyrid-4-yl)-pyridinen

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13707000

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2865203

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 20147023803

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 14381290

Country of ref document: US

Ref document number: IDP00201405083

Country of ref document: ID

ENP Entry into the national phase

Ref document number: 2014559233

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 234363

Country of ref document: IL

Ref document number: 14189543

Country of ref document: CO

Ref document number: 12014501937

Country of ref document: PH

Ref document number: MX/A/2014/010364

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2014002306

Country of ref document: CL

ENP Entry into the national phase

Ref document number: 2013224947

Country of ref document: AU

Date of ref document: 20130228

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: A201410519

Country of ref document: UA

WWE Wipo information: entry into national phase

Ref document number: 201400963

Country of ref document: EA

Ref document number: 2013707000

Country of ref document: EP

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112014020946

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112014020946

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20140826